← Fundamentals
Fundamentals · EDGAR XBRL · Health Care

LLY

Latest: Q2 FY26 · Thesis page →
Revenue$23.0B+47.7% YoY
Net income$7.1B+25.3% YoY
Free cash flow—YoY n/a
Gross margin—

Revenue vs Net income

Reported dollars from 10-Q / 10-K filings. Q4 bars are derived (annual less nine months) where the 10-K does not tag Q4 separately.

■ Revenue   ■ Net income
$0$8.3B$16.5B$24.8BQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Margin trend

Gross, operating and net margin. Margins are derived from reported dollars.

● Gross margin   ● Operating margin   ● Net margin
4%17%29%42%Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Revenue YoY growth

Year-over-year change vs the same quarter (or fiscal year) a year earlier. Shown where the prior-year period is in the 8-quarter snapshot (latest four quarters).

+54%+43%+56%+48%Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement

From 10-Q / 10-K XBRL. Values in reported dollars; EPS in $/share; share counts in shares.

Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue$11.4B$13.5B$12.7B$15.6B$17.6B$19.3B$19.8B$23.0B
YoY————+53.9%+42.6%+55.5%+47.7%
Cost of goods sold$2.2B$2.4B$2.2B$2.4B$3.0B$3.4B$3.6B$3.3B
YoY————+38.6%+40.3%+60.8%+33.5%
Gross profit————————
YoY————————
Research & development————————
YoY————————
Selling, general & administrative$2.1B$2.4B$2.5B$2.8B$2.7B$3.1B$2.9B$3.4B
YoY————+30.5%+29.1%+18.9%+24.6%
Operating income————————
YoY————————
Pretax income$1.6B$5.0B$3.5B$6.8B$7.2B$8.3B$8.8B$9.2B
YoY————+355.3%+64.1%+156.1%+36.4%
Income tax$618.1M$628.5M$697.0M$1.1B$1.6B$1.6B$1.5B$2.2B
YoY————+166.9%+159.1%+108.6%+92.8%
Net income$970.3M$4.4B$2.8B$5.7B$5.6B$6.6B$7.4B$7.1B
YoY————+475.3%+50.5%+168.1%+25.3%
EPS — basic$1.08—$3.07$6.30$6.22—$8.27$7.95
YoY————+475.9%—+169.4%+26.2%
EPS — diluted$1.07—$3.06$6.29$6.21—$8.26$7.94
YoY————+480.4%—+169.9%+26.2%
Weighted shares — basic901.0M—898.7M897.9M896.9M—894.5M892.4M
Weighted shares — diluted905.0M—900.6M899.8M898.8M—895.9M893.7M

Balance sheet

Point-in-time values at each quarter (or fiscal year) end.

Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Cash & equivalents$3.4B$3.3B$3.1B$3.4B$9.8B$7.3B$5.3B$8.9B
YoY————+190.6%+122.4%+70.8%+165.1%
Marketable securities (current)————————
YoY————————
Accounts receivable$10.3B$11.0B$12.0B$14.2B$16.1B$17.8B$18.4B$20.1B
YoY————+56.5%+61.4%+53.1%+41.7%
Inventory$7.5B$7.6B$9.3B$11.0B$12.2B$13.7B$14.5B$16.8B
YoY————+63.3%+81.1%+56.0%+52.5%
Total current assets$31.4B$32.7B$41.3B$49.9B$62.1B$55.6B$54.8B$64.7B
YoY————+97.6%+69.9%+32.9%+29.7%
Total assets$75.6B$78.7B$89.4B$100.9B$114.9B$112.5B$116.6B$142.3B
YoY————+52.0%+42.9%+30.4%+41.0%
Total current liabilities$24.7B$28.4B$30.1B$39.0B$40.1B$35.2B$36.6B$47.7B
YoY————+62.7%+24.1%+21.8%+22.4%
Total liabilities————————
YoY————————
Total equity$14.2B$14.3B$15.8B$18.3B$23.8B$26.5B$31.2B$33.9B
YoY————+67.1%+85.9%+97.9%+85.4%
Shares outstanding————————
YoY————————

Cash flow

Quarterly values derived from year-to-date filings (Q4 from the 10-K). Free cash flow = operating cash flow − capital expenditures.

Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Operating cash flow$3.7B$2.5B$1.7B$3.1B$8.8B$3.2B$5.3B$10.7B
YoY————+138.0%+30.3%+220.1%+246.3%
Capital expenditures————————
YoY————————
Free cash flow————————
YoY————————
Dividends paid$1.2B$1.2B$1.3B$1.3B$1.3B$1.3B$1.5B$1.5B
YoY————+15.0%+15.2%+15.0%+14.8%
Share repurchases$446.1M$2.1B$1.2B$692.0M$708.3M$1.5B$2.4B$1.6B
YoY————+58.8%-26.6%+96.3%+131.4%

Margins & ratios

Derived from the reported dollars above — no separate source.

Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Gross margin————————
Operating margin————————
Net margin8.5%32.6%21.7%36.4%31.7%34.4%37.4%30.9%
Free cash flow margin————————
Effective tax rate38.9%12.5%20.2%16.5%22.8%19.7%16.4%23.3%
Current ratio1.27x1.15x1.37x1.28x1.55x1.58x1.50x1.35x
Total liabilities / equity————————

Peer comparison — latest full year

Same sector (Health Care), sorted by revenue. All figures from the same EDGAR XBRL snapshot.

TickerRevenueRevenue YoYGross marginOperating marginNet marginFCF margin
LLY FY25 · this stock$65.2B+44.7%——31.7%—
UNH FY25$447.6B+11.8%—4.2%2.7%3.6%
CVS FY25$402.1B+7.8%—1.2%0.4%1.9%
CI FY25$274.9B+11.2%—3.3%——
ELV FY25$199.1B+12.5%—3.6%2.8%1.6%
JNJ FY25$94.2B+6.0%67.9%—28.5%20.9%
MRK FY25$65.0B+1.3%——28.1%19.0%
ABBV FY25$61.2B+8.6%—24.6%6.9%29.1%
BMY FY25$48.2B-0.2%——14.6%26.7%
TMO FY25$44.6B+3.9%—17.4%15.0%14.1%
ABT FY25$44.3B+5.7%—18.2%14.7%16.7%

Source: SEC EDGAR XBRL company facts (10-Q / 10-K), snapshot generated 2026-11-03 for 218 tickers. Q4 values are derived as the 10-K annual less the first nine months, since Q4 is not separately tagged in company facts; cash-flow quarterly values are derived from year-to-date filings the same way. Free cash flow = operating cash flow − capital expenditures. Blank cells mean the filing does not report that line item under a standard US-GAAP tag — nothing is estimated or filled in. Descriptive research, not investment advice. How EarnIQ builds fundamentals.